PL3061760T3 - Deuterowane pochodne benzochinoliny jako inhibitory pęcherzykowego transportera monoamin 2 - Google Patents

Deuterowane pochodne benzochinoliny jako inhibitory pęcherzykowego transportera monoamin 2

Info

Publication number: PL3061760T3
Authority: PL; Poland
Prior art keywords: deuterated; inhibitors; monoamine transporter; vesicular monoamine; benzoquinolizine
Prior art date: 2008-09-18

Application number

PL15185548T

Other languages

English (en)

Inventor

Thomas G. Gant

Manoucherhr Shahbaz

Original Assignee

Auspex Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-18

Filing date

2009-09-18

Publication date

2018-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3061760(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-18 Application filed by Auspex Pharmaceuticals, Inc. filed Critical Auspex Pharmaceuticals, Inc.

2018-07-31 Publication of PL3061760T3 publication Critical patent/PL3061760T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

PL15185548T 2008-09-18 2009-09-18 Deuterowane pochodne benzochinoliny jako inhibitory pęcherzykowego transportera monoamin 2 PL3061760T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US9789608P	2008-09-18	2008-09-18
EP13160950.5A EP2610254B1 (en)	2008-09-18	2009-09-18	Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2
EP15185548.3A EP3061760B1 (en)	2008-09-18	2009-09-18	Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
EP09820972.9A EP2326643B1 (en)	2008-09-18	2009-09-18	Benzoquinoline inhibitors of vesicular monoamine transporter 2

Publications (1)

Publication Number	Publication Date
PL3061760T3 true PL3061760T3 (pl)	2018-07-31

Family

ID=42107127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15185548T PL3061760T3 (pl)	2008-09-18	2009-09-18	Deuterowane pochodne benzochinoliny jako inhibitory pęcherzykowego transportera monoamin 2

Country Status (20)

Country	Link
US (15)	US8524733B2 (pl)
EP (4)	EP2610254B1 (pl)
JP (3)	JP5616345B2 (pl)
CN (2)	CN104311552A (pl)
AU (1)	AU2009303758B8 (pl)
BR (1)	BRPI0913457B8 (pl)
CA (2)	CA2736409C (pl)
CY (1)	CY1120060T1 (pl)
DK (2)	DK3061760T3 (pl)
ES (4)	ES2896678T3 (pl)
HK (3)	HK1186728A1 (pl)
HR (1)	HRP20180239T1 (pl)
HU (1)	HUE038158T2 (pl)
LT (1)	LT3061760T (pl)
NO (1)	NO3061760T3 (pl)
NZ (1)	NZ591615A (pl)
PL (1)	PL3061760T3 (pl)
PT (1)	PT3061760T (pl)
SI (1)	SI3061760T1 (pl)
WO (1)	WO2010044981A2 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3061760T (lt) *	2008-09-18	2018-02-26	Auspex Pharmaceuticals, Inc.	Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
UA102336C2 (uk) *	2009-11-10	2013-06-25	Пфайзер Інк.	N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
EP3351247A1 (en) *	2010-06-01	2018-07-25	Auspex Pharmaceutical, Inc.	Benzoquinolone inhibitors of vmat2
US9572880B2 (en)	2010-08-27	2017-02-21	Sienna Biopharmaceuticals, Inc.	Ultrasound delivery of nanoparticles
PL3210591T3 (pl)	2010-08-27	2019-08-30	Sienna Biopharmaceuticals, Inc.	Kompozycje i sposoby do termomodulacji celowanej
WO2012081031A1 (en) *	2010-12-15	2012-06-21	Enaltec Labs Pvt. Ltd.	Process for preparing tetrabenazine
NZ705372A (en) *	2012-09-18	2018-07-27	Auspex Pharmaceuticals Inc	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en)	2012-09-18	2017-01-24	Auspex Pharmaceuticals, Inc.	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2646809C2 (ru)	2012-10-11	2018-03-07	Нанокомпозикс, Инк.	Композиции серебряных нанопластин и способы
EP2951178A4 (en)	2013-01-31	2016-07-06	Auspex Pharmaceuticals Inc	VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
US20160207917A1 (en) *	2013-09-27	2016-07-21	Auspex Pharmaceuticals, Inc.	Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) *	2013-11-22	2015-05-28	Auspex Pharmaceuticals, Inc.	Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2930167A1 (en) *	2013-11-22	2015-05-28	Auspex Pharmaceuticals, Inc.	Methods of treating abnormal muscular activity
AU2014357518A1 (en)	2013-12-03	2016-06-09	Auspex Pharmaceuticals, Inc.	Methods of manufacturing benzoquinoline compounds
US20160346270A1 (en)	2014-01-27	2016-12-01	Auspex Pharmaceuticals, Inc.	Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016010071A (es) *	2014-02-07	2017-04-27	Neurocrine Biosciences Inc	Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
MX2016010213A (es) *	2014-02-07	2017-04-13	Auspex Pharmaceuticals Inc	Formulaciones farmaceuticas novedosas.
US20170071932A1 (en)	2014-05-06	2017-03-16	Neurocrine Biosciences, Inc.	Treatment of hyperkinetic movement disorders
MA41557A (fr) *	2015-02-18	2017-12-26	Auspex Pharmaceuticals Inc	Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
ES2927262T3 (es)	2015-03-06	2022-11-03	Auspex Pharmaceuticals Inc	Métodos para el tratamiento de trastornos de movimiento involuntario anormales
US20180071024A1 (en) *	2015-03-20	2018-03-15	Sienna Biopharmaceuticals, Inc.	Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles
EP3368534B1 (en)	2015-10-30	2021-01-27	Neurocrine Biosciences, Inc.	Valbenazine ditosylate and polymorphs thereof
MA44127A (fr)	2015-12-23	2018-10-31	Neurocrine Biosciences Inc	Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
US10479787B2 (en)	2016-04-22	2019-11-19	Lupin Limited	Process for preparation of tetrabenazine and deutetrabenazine
WO2017221169A1 (en)	2016-06-24	2017-12-28	Lupin Limited	Premixes of deutetrabenazine
CN107936008B (zh) *	2016-10-13	2022-06-14	泰州华元医药科技有限公司	氘代化合物及其医药用途
TW201827051A (zh)	2016-12-02	2018-08-01	美商神經性分泌生物科學公司	戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en)	2017-01-10	2018-07-19	Sandoz Ag	Crystalline valbenazine free base
MX2019008853A (es)	2017-01-27	2019-09-11	Neurocrine Biosciences Inc	Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
WO2018153632A1 (en)	2017-02-27	2018-08-30	Sandoz Ag	Crystalline forms of valbenazine salts
WO2018164996A1 (en)	2017-03-06	2018-09-13	Neurocrine Biosciences, Inc.	Dosing regimen for valbenazine
KR20200003791A (ko) *	2017-03-15	2020-01-10	오스펙스 파마슈티칼스, 인코포레이티드	듀테트라베나진의 유사체, 이의 제조 및 용도
JOP20190239A1 (ar)	2017-04-19	2019-10-09	Neurocrine Biosciences Inc	مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en)	2017-04-26	2018-11-01	Neurocrine Biosciences, Inc.	Use of valbenazine for treating levodopa-induced dyskinesia
IL273300B2 (en)	2017-09-21	2024-06-01	Neurocrine Biosciences Inc	High dose valbenazine formulation and related preparations, methods and kits
US10993941B2 (en)	2017-10-10	2021-05-04	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
EA202090932A1 (ru)	2017-10-10	2021-05-20	Нейрокрин Байосайенсиз, Инк	Способы введения некоторых vmat2-ингибиторов
US10786495B2 (en) *	2017-10-10	2020-09-29	The Regents Of The University Of California	Vesicular monoamine transporter 2 inhibitors for treating stuttering
WO2019130252A2 (en) *	2017-12-29	2019-07-04	Mylan Laboratories Ltd	Methods and intermediates for preparing deutetrabenazine
US11806326B2 (en)	2018-01-29	2023-11-07	Jonathan Sackner-Bernstein	Methods for dopamine modulation in human neurologic diseases
US11505549B2 (en) *	2018-02-01	2022-11-22	Lakshmi Prasad ALAPARTHI	Process for preparation of Deutetrabenazine
WO2019166962A1 (en)	2018-03-01	2019-09-06	Mylan Laboratories Ltd	Deutetrabenazine polymorphs and methods for their preparation
KR20210005623A (ko) *	2018-04-25	2021-01-14	신케이 테라퓨틱스 엘엘씨	테트라베나진 경피 전달 장치
CA3043075A1 (en)	2018-05-14	2019-11-14	Apotex Inc	Novel crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3806856A1 (en)	2018-06-14	2021-04-21	Neurocrine Biosciences, Inc.	Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN108794337A (zh) *	2018-07-10	2018-11-13	上海华堇生物技术有限责任公司	一种3,4-二羟基-β-硝基苯乙烯的新制备方法
JOP20200336A1 (ar)	2018-08-15	2020-12-22	Neurocrine Biosciences Inc	طرق إعطاء مثبطات vmat2 معينة
WO2020079165A1 (en)	2018-10-18	2020-04-23	Oncopeptides Ab	Compounds containing deuterium
BR112021011386A2 (pt)	2018-12-13	2021-08-31	Auspex Pharmaceuticals, Inc	Deutetrabenazina para o tratamento da discinesia na paralisia cerebral
CN113438990B (zh)	2019-02-22	2023-06-23	株式会社Ihi	推力箔片轴承、推力箔片轴承的底板的制造方法
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
JP7419571B2 (ja)	2020-06-10	2024-01-22	オースペックスファーマシューティカルズインコーポレイテッド	デューテトラベナジンを含む浸透性剤形及びその使用方法
WO2022061058A1 (en)	2020-09-17	2022-03-24	Auspex Pharmaceuticals, Inc.	Multiparticulate dosage forms comprising deutetrabenazine
IL301703A (en)	2020-10-12	2023-05-01	Auspex Pharmaceuticals Inc	Pharmaceutical preparations that are delayed in the stomach containing deuterabenzene
IL305054A (en)	2021-03-22	2023-10-01	Neurocrine Biosciences Inc	VMAT2 inhibitors and methods of use
WO2023278987A1 (en)	2021-06-30	2023-01-05	Neurocrine Biosciences, Inc.	Valbenazine for use in the add-on treatment of schizophrenia
EP4401707A1 (en)	2021-09-17	2024-07-24	Auspex Pharmaceuticals, Inc.	Multiparticulate dosage forms comprising deutetrabenazine
WO2023172849A1 (en)	2022-03-07	2023-09-14	Neurocrine Biosciences, Inc.	Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
WO2023240186A1 (en)	2022-06-08	2023-12-14	Auspex Pharmaceuticals, Inc.	Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2830993A (en)		1958-04-15		Quinolizine derivatives
US3045021A (en)	1959-09-24	1962-07-17	Hoffmann La Roche	Preparation of substituted 2-oxobenzoquinolizines
DE1253271B (de) *	1961-03-28	1967-11-02	Mta	Verfahren zur Herstellung von 2-Oxo-1, 2, 3, 4, 6, 7-hexahydro-11bH-benzo[a]chinolizinen
US4316897A (en) *	1980-09-10	1982-02-23	Hoffmann-La Roche Inc.	Method of lowering serum prolactin
KR20040068613A (ko) *	1994-03-25	2004-07-31	이소테크니카 인코포레이티드	중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6221335B1 (en) *	1994-03-25	2001-04-24	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
US6440710B1 (en) *	1998-12-10	2002-08-27	The Scripps Research Institute	Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) *	1999-12-03	2003-12-18	Pfizer Products Inc., Groton	Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
EP1134290A3 (en) *	2000-03-14	2004-01-02	Pfizer Products Inc.	Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
TW200413273A (en) *	2002-11-15	2004-08-01	Wako Pure Chem Ind Ltd	Heavy hydrogenation method of heterocyclic rings
US20080026081A1 (en) *	2003-11-21	2008-01-31	Axel Unterbeck	Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate
GB2410947B (en) *	2004-02-11	2008-09-17	Cambridge Lab Ltd	Pharmaceutical compounds
WO2006053067A2 (en)	2004-11-09	2006-05-18	Prestwick Pharmaceuticals, Inc.	Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
JP4801096B2 (ja)	2005-01-19	2011-10-26	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
US20080033011A1 (en) *	2005-07-29	2008-02-07	Concert Pharmaceuticals Inc.	Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) *	2006-02-10	2010-07-06	Sigma-Aldrich Co.	Stabilized deuteroborane-tetrahydrofuran complex
ES2525932T3 (es)	2006-05-02	2015-01-02	The Trustees Of The University Of Pennsylvania	Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
EA018378B1 (ru)	2006-11-08	2013-07-30	Ньюрокрайн Байосайенсиз, Инк.	ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EP2078026B1 (en)	2006-11-21	2012-01-04	Rigel Pharmaceuticals, Inc.	Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
WO2008112278A2 (en)	2007-03-12	2008-09-18	The Trustees Of Columbia University In The City Of New York	Methods and compositions for modulating insulin secretion and glucose metabolism
US7897768B2 (en) *	2007-06-08	2011-03-01	General Electric Company	Method for making tetrabenazine compounds
JP5582535B2 (ja) *	2007-06-29	2014-09-03	クラレンスピーティーワイエルティーディー	点眼投与による神経疾患または精神神経疾患の治療または予防
WO2009124357A1 (en)	2008-04-10	2009-10-15	Malvin Leonard Eutick	Fast dissolving oral formulations for critical drugs
GB2462611A (en)	2008-08-12	2010-02-17	Cambridge Lab	Pharmaceutical composition comprising tetrabenazine
LT3061760T (lt)	2008-09-18	2018-02-26	Auspex Pharmaceuticals, Inc.	Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
US20100113496A1 (en) *	2008-09-25	2010-05-06	Auspex Pharmaceuticals, Inc.	Piperidine modulators of vmat2
JP2013501810A (ja)	2009-08-12	2013-01-17	ヴァリーントインターナショナル（バルバドス）エスアールエル	医薬組成物
KR20120120970A (ko)	2010-02-24	2012-11-02	오스펙스 파마슈티칼스, 인코포레이티드	티로신 키나아제의 트리메톡시페닐 저해제
EP3351247A1 (en) *	2010-06-01	2018-07-25	Auspex Pharmaceutical, Inc.	Benzoquinolone inhibitors of vmat2

2009
- 2009-09-18 LT LTEP15185548.3T patent/LT3061760T/lt unknown
- 2009-09-18 CN CN201410524867.7A patent/CN104311552A/zh active Pending
- 2009-09-18 EP EP13160950.5A patent/EP2610254B1/en not_active Not-in-force
- 2009-09-18 EP EP15185548.3A patent/EP3061760B1/en active Active
- 2009-09-18 WO PCT/US2009/057480 patent/WO2010044981A2/en active Application Filing
- 2009-09-18 US US12/562,621 patent/US8524733B2/en active Active
- 2009-09-18 ES ES17199778T patent/ES2896678T3/es active Active
- 2009-09-18 DK DK15185548.3T patent/DK3061760T3/en active
- 2009-09-18 PT PT151855483T patent/PT3061760T/pt unknown
- 2009-09-18 JP JP2011527995A patent/JP5616345B2/ja active Active
- 2009-09-18 CN CN200980141378.0A patent/CN102186848B/zh active Active
- 2009-09-18 CA CA2736409A patent/CA2736409C/en active Active
- 2009-09-18 ES ES13160950.5T patent/ES2563820T3/es active Active
- 2009-09-18 EP EP17199778.6A patent/EP3345905B1/en active Active
- 2009-09-18 DK DK09820972.9T patent/DK2326643T3/da active
- 2009-09-18 HU HUE15185548A patent/HUE038158T2/hu unknown
- 2009-09-18 SI SI200931797T patent/SI3061760T1/en unknown
- 2009-09-18 PL PL15185548T patent/PL3061760T3/pl unknown
- 2009-09-18 EP EP09820972.9A patent/EP2326643B1/en active Active
- 2009-09-18 AU AU2009303758A patent/AU2009303758B8/en active Active
- 2009-09-18 BR BRPI0913457A patent/BRPI0913457B8/pt active IP Right Grant
- 2009-09-18 CA CA2972242A patent/CA2972242A1/en not_active Abandoned
- 2009-09-18 NO NO15185548A patent/NO3061760T3/no unknown
- 2009-09-18 ES ES09820972T patent/ES2425623T3/es active Active
- 2009-09-18 ES ES15185548.3T patent/ES2652289T3/es active Active
- 2009-09-18 NZ NZ591615A patent/NZ591615A/en unknown
2013
- 2013-07-03 US US13/934,960 patent/US20130296360A1/en not_active Abandoned
- 2013-12-20 HK HK13114111.0A patent/HK1186728A1/zh not_active IP Right Cessation
2014
- 2014-03-25 US US14/225,010 patent/US20140206713A1/en not_active Abandoned
- 2014-03-25 US US14/224,883 patent/US20140206712A1/en not_active Abandoned
- 2014-08-08 US US14/454,911 patent/US20140350044A1/en not_active Abandoned
- 2014-09-11 JP JP2014185634A patent/JP5970037B2/ja active Active
- 2014-10-15 US US14/515,047 patent/US20150080427A1/en not_active Abandoned
2015
- 2015-07-23 US US14/807,364 patent/US20150328207A1/en not_active Abandoned
2016
- 2016-02-11 US US15/041,571 patent/US20160158220A1/en not_active Abandoned
- 2016-04-08 US US15/094,517 patent/US20160220558A1/en not_active Abandoned
- 2016-07-08 JP JP2016136178A patent/JP6138322B2/ja active Active
- 2016-09-01 US US15/254,912 patent/US20160367548A1/en not_active Abandoned
- 2016-09-06 US US15/257,372 patent/US20160375005A1/en not_active Abandoned
- 2016-09-21 HK HK16111056.0A patent/HK1222853A1/zh unknown
2017
- 2017-02-28 US US15/445,402 patent/US20170166562A1/en not_active Abandoned
2018
- 2018-02-07 CY CY20181100152T patent/CY1120060T1/el unknown
- 2018-02-07 HR HRP20180239TT patent/HRP20180239T1/hr unknown
- 2018-12-05 US US16/210,077 patent/US20190375746A1/en not_active Abandoned
2019
- 2019-01-08 HK HK19100241.6A patent/HK1257880A1/zh unknown
2020
- 2020-03-17 US US16/821,067 patent/US20200347048A1/en not_active Abandoned
2021
- 2021-11-05 US US17/519,922 patent/US20220267317A1/en active Pending

Also Published As

Publication number	Publication date
HK1222853A1 (zh)	2017-07-14
EP2326643B1 (en)	2013-05-29
ES2563820T3 (es)	2016-03-16
CA2736409C (en)	2017-07-11
US20140206712A1 (en)	2014-07-24
EP3061760B1 (en)	2017-11-08
WO2010044981A3 (en)	2010-06-17
DK2326643T3 (da)	2013-08-05
US20140350044A1 (en)	2014-11-27
EP3345905B1 (en)	2021-09-01
US20160158220A1 (en)	2016-06-09
US20170166562A1 (en)	2017-06-15
HRP20180239T1 (hr)	2018-05-18
CN102186848A (zh)	2011-09-14
JP6138322B2 (ja)	2017-05-31
SI3061760T1 (en)	2018-04-30
PT3061760T (pt)	2018-01-04
ES2652289T3 (es)	2018-02-01
AU2009303758B2 (en)	2014-10-23
AU2009303758A8 (en)	2015-02-19
US8524733B2 (en)	2013-09-03
EP3345905A1 (en)	2018-07-11
BRPI0913457A2 (pt)	2020-06-09
HK1257880A1 (zh)	2019-11-01
EP3061760A1 (en)	2016-08-31
US20220267317A1 (en)	2022-08-25
BRPI0913457B8 (pt)	2021-08-31
US20130296360A1 (en)	2013-11-07
EP2610254A1 (en)	2013-07-03
DK3061760T3 (en)	2018-02-05
US20100130480A1 (en)	2010-05-27
ES2896678T3 (es)	2022-02-25
CA2736409A1 (en)	2010-04-22
AU2009303758B8 (en)	2015-02-19
US20160367548A1 (en)	2016-12-22
ES2425623T3 (es)	2013-10-16
JP2012503010A (ja)	2012-02-02
JP5616345B2 (ja)	2014-10-29
EP2610254B1 (en)	2015-11-25
US20150328207A1 (en)	2015-11-19
JP5970037B2 (ja)	2016-08-17
WO2010044981A2 (en)	2010-04-22
US20200347048A1 (en)	2020-11-05
CA2972242A1 (en)	2010-04-22
CY1120060T1 (el)	2018-12-12
US20190375746A1 (en)	2019-12-12
CN102186848B (zh)	2014-11-12
BRPI0913457B1 (pt)	2021-07-20
US20160220558A1 (en)	2016-08-04
CN104311552A (zh)	2015-01-28
LT3061760T (lt)	2018-02-26
NO3061760T3 (pl)	2018-04-07
US20160375005A1 (en)	2016-12-29
AU2009303758A1 (en)	2010-04-22
US20140206713A1 (en)	2014-07-24
EP2326643A4 (en)	2012-03-21
HUE038158T2 (hu)	2018-09-28
JP2016172782A (ja)	2016-09-29
JP2015007124A (ja)	2015-01-15
NZ591615A (en)	2012-07-27
HK1186728A1 (zh)	2014-03-21
EP2326643A2 (en)	2011-06-01
US20150080427A1 (en)	2015-03-19

Publication	Publication Date	Title
HK1257880A1 (zh)	2019-11-01	氘化的苯並喹啉衍生物作為纈氨酸單胺轉運蛋白2的抑制劑
HRP20180662T1 (hr)	2018-06-01	1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
TWI347321B (en)	2011-08-21	Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2178840T3 (pl)	2012-05-31	Pochodne kwasu azabifenyloaminobenzoesowego jako inhibitory dhodh
HK1139936A1 (en)	2010-09-30	Substituted pyrimidodiazepines useful as plk1 inhibitors
HK1143367A1 (en)	2010-12-31	Quinazolin-oxime derivatives as hsp90 inhibitors hsp90 -
ZA200807263B (en)	2009-11-25	Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors
DK2010496T3 (da)	2010-11-08	4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
SI2225238T1 (sl)	2014-12-31	Derivati amidov 6,7-dihidro-5H-imidazo(1,2-a)imidazol-3-karboksilne kisline
ZA200908612B (en)	2010-11-24	1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
IL193481A0 (en)	2009-05-04	4-phenyl-thiazole-5-carboxylic acids and 4 - phenyl - thiazole - 5 - carboxylic acid amides as plk1 inhibitors
IL196000A0 (en)	2009-09-01	2-arylindole derivatives as npges-i inhibitors
ZA200808598B (en)	2009-12-30	Pyrrolopyrimidine derivatives used as HSP90 inhibitors
ZA201000383B (en)	2010-09-29	Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors